Cyclic peptides discriminate BCL-2 and its clinical mutants from BCL-X
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
17 Feb 2024
17 Feb 2024
Historique:
received:
23
02
2023
accepted:
06
02
2024
medline:
18
2
2024
pubmed:
18
2
2024
entrez:
17
2
2024
Statut:
epublish
Résumé
Overexpressed pro-survival B-cell lymphoma-2 (BCL-2) family proteins BCL-2 and BCL-X
Identifiants
pubmed: 38368459
doi: 10.1038/s41467-024-45848-1
pii: 10.1038/s41467-024-45848-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1476Subventions
Organisme : Natural Science Foundation of Shandong Province (Shandong Provincial Natural Science Foundation)
ID : ZR2021JQ30
Informations de copyright
© 2024. The Author(s).
Références
Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456–1462 (1995).
pubmed: 7878464
doi: 10.1126/science.7878464
Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124, 1–6 (1994).
pubmed: 8294493
doi: 10.1083/jcb.124.1.1
Lessene, G., Czabotar, P. E. & Colman, P. M. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov. 7, 989–1000 (2008).
pubmed: 19043450
doi: 10.1038/nrd2658
Letai, A. G. Diagnosing and exploiting cancer’s addiction to blocks in apoptosis. Nat. Rev. Cancer 8, 121–132 (2008).
pubmed: 18202696
doi: 10.1038/nrc2297
Cheng, E. H., Levine, B., Boise, L. H., Thompson, C. B. & Hardwick, J. M. Bax-independent inhibition of apoptosis by Bcl-XL. Nature 379, 554–556 (1996).
pubmed: 8596636
doi: 10.1038/379554a0
Cheng, E. H. et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 8, 705–711 (2001).
pubmed: 11583631
doi: 10.1016/S1097-2765(01)00320-3
Bose, P., Gandhi, V. & Konopleva, M. Pathways and mechanisms of venetoclax resistance. Leuk. lymphoma 58, 1–17 (2017).
pubmed: 28140720
doi: 10.1080/10428194.2017.1283032
Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202–208 (2013).
pubmed: 23291630
doi: 10.1038/nm.3048
van Delft, M. F. et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389–399 (2006).
pubmed: 17097561
pmcid: 2953559
doi: 10.1016/j.ccr.2006.08.027
Vaux, D. L., Cory, S. & Adams, J. M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335, 440–442 (1988).
pubmed: 3262202
doi: 10.1038/335440a0
Amundson, S. A. et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60, 6101–6110 (2000).
pubmed: 11085534
Tao, Z. F. et al. Structure-Based Design of A-1293102, a Potent and Selective BCL-X(L) Inhibitor. ACS Med. Chem. Lett. 12, 1011–1016 (2021).
pubmed: 34141086
pmcid: 8201748
doi: 10.1021/acsmedchemlett.1c00162
Murray, J. B. et al. Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1. ACS Omega 4, 8892–8906 (2019).
pubmed: 31459977
pmcid: 6648477
doi: 10.1021/acsomega.9b00611
Ku, B., Liang, C., Jung, J. U. & Oh, B. H. Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res. 21, 627–641 (2011).
pubmed: 21060336
doi: 10.1038/cr.2010.149
Sattler, M. et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983–986 (1997).
pubmed: 9020082
doi: 10.1126/science.275.5302.983
Liu, X., Dai, S., Zhu, Y., Marrack, P. & Kappler, J. W. The structure of a Bcl-xL/Bim fragment complex: implications for Bim function. Immunity 19, 341–352 (2003).
pubmed: 14499110
doi: 10.1016/S1074-7613(03)00234-6
Czabotar, P. E. et al. Mutation to Bax beyond the BH3 domain disrupts interactions with pro-survival proteins and promotes apoptosis. J. Biol. Chem. 286, 7123–7131 (2011).
pubmed: 21199865
pmcid: 3044969
doi: 10.1074/jbc.M110.161281
Petros, A. M. et al. Solution structure of the antiapoptotic protein bcl-2. Proc. Natl Acad. Sci. USA 98, 3012–3017 (2001).
pubmed: 11248023
pmcid: 30598
doi: 10.1073/pnas.041619798
Muchmore, S. W. et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381, 335–341 (1996).
pubmed: 8692274
doi: 10.1038/381335a0
Aritomi, M. et al. Crystal structure of rat Bcl-xL. Implications for the function of the Bcl-2 protein family. J. Biol. Chem. 272, 27886–27892 (1997).
pubmed: 9346936
doi: 10.1074/jbc.272.44.27886
Bruncko, M. et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J. Med. Chem. 50, 641–662 (2007).
pubmed: 17256834
doi: 10.1021/jm061152t
Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681 (2005).
pubmed: 15902208
doi: 10.1038/nature03579
Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421–3428 (2008).
pubmed: 18451170
doi: 10.1158/0008-5472.CAN-07-5836
Davids, M. S. & Letai, A. ABT-199: taking dead aim at BCL-2. Cancer Cell 23, 139–141 (2013).
pubmed: 23410971
pmcid: 3693952
doi: 10.1016/j.ccr.2013.01.018
Anderson, M. A. et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood 129, 3362–3370 (2017).
pubmed: 28473407
doi: 10.1182/blood-2017-01-763003
Thijssen, R. & Roberts, A. W. Venetoclax in Lymphoid Malignancies: New Insights, More to Learn. Cancer Cell 36, 341–343 (2019).
pubmed: 31614111
doi: 10.1016/j.ccell.2019.09.008
Blombery, P. et al. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood 135, 773–777 (2020).
pubmed: 31951646
pmcid: 7146015
doi: 10.1182/blood.2019004205
Scott, D. E., Bayly, A. R., Abell, C. & Skidmore, J. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat. Rev. Drug Discov. 15, 533–550 (2016).
pubmed: 27050677
doi: 10.1038/nrd.2016.29
Blombery, P. et al. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discov. 9, 342–353 (2019).
pubmed: 30514704
doi: 10.1158/2159-8290.CD-18-1119
Thangavadivel, S. & Byrd, J. C. Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL. Cancer Discov. 9, 320–322 (2019).
pubmed: 30824485
doi: 10.1158/2159-8290.CD-19-0029
Birkinshaw, R. W. et al. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nat. Commun. 10, 2385 (2019).
pubmed: 31160589
pmcid: 6547681
doi: 10.1038/s41467-019-10363-1
Tausch, E. et al. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica 104, e434–e437 (2019).
pubmed: 31004028
pmcid: 6717583
doi: 10.3324/haematol.2019.222588
Nielsen, D. S. et al. Orally Absorbed Cyclic Peptides. Chem. Rev. 117, 8094–8128 (2017).
pubmed: 28541045
doi: 10.1021/acs.chemrev.6b00838
Muttenthaler, M., King, G. F., Adams, D. J. & Alewood, P. F. Trends in peptide drug discovery. Nat. Rev. Drug Discov. 20, 309–325 (2021).
pubmed: 33536635
doi: 10.1038/s41573-020-00135-8
Kaspar, A. A. & Reichert, J. M. Future directions for peptide therapeutics development. Drug Discov. Today 18, 807–817 (2013).
pubmed: 23726889
doi: 10.1016/j.drudis.2013.05.011
Lee, E. F. et al. Structural basis of Bcl-xL recognition by a BH3-mimetic α/β-peptide generated by sequence-based design. Chembiochem 12, 2025–2032 (2011).
pubmed: 21744457
pmcid: 3263372
doi: 10.1002/cbic.201100314
Checco, J. W. et al. α/β-Peptide Foldamers Targeting Intracellular Protein-Protein Interactions with Activity in Living Cells. J. Am. Chem. Soc. 137, 11365–11375 (2015).
pubmed: 26317395
pmcid: 4687753
doi: 10.1021/jacs.5b05896
LaBelle, J. L. et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J. Clin. Invest. 122, 2018–2031 (2012).
pubmed: 22622039
pmcid: 3366394
doi: 10.1172/JCI46231
Okamoto, T. et al. Stabilizing the Pro-Apoptotic BimBH3 Helix (BimSAHB) Does Not Necessarily Enhance Affinity or Biological Activity. ACS Chem. Biol. 8, 297–302 (2013).
pubmed: 23151250
doi: 10.1021/cb3005403
Wang, D., Liao, W. & Arora, P. S. Enhanced metabolic stability and protein-binding properties of artificial alpha helices derived from a hydrogen-bond surrogate: application to Bcl-xL. Angew. Chem. Int. Ed. 44, 6525–6529 (2005).
doi: 10.1002/anie.200501603
Walensky, L. D. et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466–1470 (2004).
pubmed: 15353804
pmcid: 1360987
doi: 10.1126/science.1099191
Edwards, A. L. et al. Cellular Uptake and Ultrastructural Localization Underlie the Pro-apoptotic Activity of a Hydrocarbon-stapled BIM BH3 Peptide. ACS Chem. Biol. 10, 2149–2157 (2015).
pubmed: 26151238
pmcid: 6839450
doi: 10.1021/acschembio.5b00214
Patel, K. et al. Cyclic peptides can engage a single binding pocket through highly divergent modes. Proc. Natl Acad. Sci. USA 117, 26728–26738 (2020).
pubmed: 33046654
pmcid: 7604503
doi: 10.1073/pnas.2003086117
Zheng, X. et al. Condensation of 2-((Alkylthio)(aryl)methylene)malononitrile with 1,2-Aminothiol as a Novel Bioorthogonal Reaction for Site-Specific Protein Modification and Peptide Cyclization. J. Am. Chem. Soc. 142, 5097–5103 (2020).
pubmed: 32108479
doi: 10.1021/jacs.9b11875
Diepstraten, S. T. et al. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat. Rev. Cancer 22, 45–64 (2022).
pubmed: 34663943
doi: 10.1038/s41568-021-00407-4
Sora, V. & Papaleo, E. Structural Details of BH3 Motifs and BH3-Mediated Interactions: an Updated Perspective. Front. Mol. Biosci. 9, 864874 (2022).
pubmed: 35685242
pmcid: 9171138
doi: 10.3389/fmolb.2022.864874
Fresquet, V., Rieger, M., Carolis, C., García-Barchino, M. J. & Martinez-Climent, J. A. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood 123, 4111–4119 (2014).
pubmed: 24786774
doi: 10.1182/blood-2014-03-560284
Taddese, B., Garnier, A., Abdi, H., Henrion, D. & Chabbert, M. Deciphering collaborative sidechain motions in proteins during molecular dynamics simulations. Sci. Rep. 10, 15901 (2020).
pubmed: 32985550
pmcid: 7522237
doi: 10.1038/s41598-020-72766-1
Jumper, J. M., Faruk, N. F., Freed, K. F. & Sosnick, T. R. Accurate calculation of side chain packing and free energy with applications to protein molecular dynamics. PLoS Comput. Biol. 14, e1006342 (2018).
pubmed: 30589846
pmcid: 6307715
doi: 10.1371/journal.pcbi.1006342
Heinis, C., Rutherford, T., Freund, S. & Winter, G. Phage-encoded combinatorial chemical libraries based on bicyclic peptides. Nat. Chem. Biol. 5, 502–507 (2009).
pubmed: 19483697
doi: 10.1038/nchembio.184
Owens, A. E., Iannuzzelli, J. A., Gu, Y. & Fasan, R. MOrPH-PhD: An Integrated Phage Display Platform for the Discovery of Functional Genetically Encoded Peptide Macrocycles. ACS Central Sci. 6, 368–381 (2020).
doi: 10.1021/acscentsci.9b00927
Sojitra, M. et al. Genetically encoded multivalent liquid glycan array displayed on M13 bacteriophage. Nat. Chem. Biol. 17, 806–816 (2021).
pubmed: 33958792
pmcid: 8380037
doi: 10.1038/s41589-021-00788-5
Bhardwaj, G. et al. Accurate de novo design of membrane-traversing macrocycles. Cell 185, 3520–3532.e3526 (2022).
pubmed: 36041435
pmcid: 9490236
doi: 10.1016/j.cell.2022.07.019
Jo, M. J. et al. Regulation of cancer cell death by a novel compound, C604, in a c-Myc-overexpressing cellular environment. Eur. J. Pharmacol. 769, 257–265 (2015).
pubmed: 26607468
doi: 10.1016/j.ejphar.2015.11.027
Rivas-Carrillo, J. D. et al. Cell-permeable pentapeptide V5 inhibits apoptosis and enhances insulin secretion, allowing experimental single-donor islet transplantation in mice. Diabetes 56, 1259–1267 (2007).
pubmed: 17287463
doi: 10.2337/db06-1679
Lessene, G. et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat. Chem. Biol. 9, 390–397 (2013).
pubmed: 23603658
doi: 10.1038/nchembio.1246
Wang, X. et al. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor. J. Med. Chem. 65, 3123–3133 (2022).
pubmed: 34889605
doi: 10.1021/acs.jmedchem.1c01688
Mao, Z. et al. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discov. 8, 5 (2022).
pubmed: 35075146
pmcid: 8786924
doi: 10.1038/s41421-021-00368-w
Casara, P. et al. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget 9, 20075–20088 (2018).
pubmed: 29732004
pmcid: 5929447
doi: 10.18632/oncotarget.24744
Lipinski, C. A. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov. Today Technol. 1, 337–341 (2004).
pubmed: 24981612
doi: 10.1016/j.ddtec.2004.11.007
Naylor, M. R., Bockus, A. T., Blanco, M.-J. & Lokey, R. S. Cyclic peptide natural products chart the frontier of oral bioavailability in the pursuit of undruggable targets. Curr. Opin. Chem. Biol. 38, 141–147 (2017).
pubmed: 28570865
doi: 10.1016/j.cbpa.2017.04.012
Peraro, L. & Kritzer, J. A. Emerging Methods and Design Principles for Cell-Penetrant Peptides. Angew. Chem. Int. Ed. 57, 11868–11881 (2018).
doi: 10.1002/anie.201801361
Wang, C. K., Swedberg, J. E., Harvey, P. J., Kaas, Q. & Craik, D. J. Conformational Flexibility Is a Determinant of Permeability for Cyclosporin. J. Phys. Chem. B 122, 2261–2276 (2018).
pubmed: 29400464
doi: 10.1021/acs.jpcb.7b12419
Minor, W., Cymborowski, M., Otwinowski, Z. & Chruszcz, M. HKL-3000: the integration of data reduction and structure solution–from diffraction images to an initial model in minutes. Acta Crystallogr. 62, 859–866 (2006).
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
pubmed: 19461840
pmcid: 2483472
doi: 10.1107/S0021889807021206
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. 66, 486–501 (2010).
Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat. Methods 14, 71–73 (2017).
pubmed: 27819658
doi: 10.1038/nmeth.4067
Paesani, F., Zhang, W., Case, D. A., Cheatham, T. E. 3rd & Voth, G. A. An accurate and simple quantum model for liquid water. J. Chem. Phys. 125, 184507 (2006).
pubmed: 17115765
doi: 10.1063/1.2386157
Vanommeslaeghe, K. et al. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 31, 671–690 (2010).
pubmed: 19575467
pmcid: 2888302
doi: 10.1002/jcc.21367
Woods, R. J. & Chappelle, R. Restrained electrostatic potential atomic partial charges for condensed-phase simulations of carbohydrates. Theochem. 527, 149–156 (2000).
pubmed: 25309012
pmcid: 4191892
doi: 10.1016/S0166-1280(00)00487-5
Neese, F., Wennmohs, F., Becker, U. & Riplinger, C. The ORCA quantum chemistry program package. J. Chem. Phys. 152, 224108 (2020).
pubmed: 32534543
doi: 10.1063/5.0004608
Lu, T. & Chen, F. Multiwfn: a multifunctional wavefunction analyzer. J. Comput. Chem. 33, 580–592 (2012).
pubmed: 22162017
doi: 10.1002/jcc.22885
Grimme, S., Antony, J., Ehrlich, S. & Krieg, H. A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu. J. Chem. Phys. 132, 154104 (2010).
pubmed: 20423165
doi: 10.1063/1.3382344
Marenich, A. V., Cramer, C. J. & Truhlar, D. G. Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions. J. Phys. Chem. B 113, 6378–6396 (2009).
pubmed: 19366259
doi: 10.1021/jp810292n
Eastman, P. et al. OpenMM 7: Rapid development of high performance algorithms for molecular dynamics. PLoS Comput. Biol. 13, e1005659 (2017).
pubmed: 28746339
pmcid: 5549999
doi: 10.1371/journal.pcbi.1005659
McGibbon, R. T. et al. MDTraj: A Modern Open Library for the Analysis of Molecular Dynamics Trajectories. Biophys. J. 109, 1528–1532 (2015).
pubmed: 26488642
pmcid: 4623899
doi: 10.1016/j.bpj.2015.08.015
Zha, M., Lin, P., Yao, H., Zhao, Y. & Wu, C. A phage display-based strategy for the de novo creation of disulfide-constrained and isomer-free bicyclic peptide affinity reagents. Chem. Commun. 54, 4029–4032 (2018).
doi: 10.1039/C7CC09142G
Bernal, F., Tyler, A. F., Korsmeyer, S. J., Walensky, L. D. & Verdine, G. L. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J. Am. Chem. Soc. 129, 2456–2457 (2007).
pubmed: 17284038
pmcid: 6333086
doi: 10.1021/ja0693587
Jeong, W. J., Lee, M. S. & Lim, Y. B. Helix stabilized, thermostable, and protease-resistant self-assembled peptide nanostructures as potential inhibitors of protein-protein interactions. Biomacromolecules 14, 2684–2689 (2013).
pubmed: 23844716
doi: 10.1021/bm400532y
Nikolovska-Coleska, Z. et al. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal. Biochem. 332, 261–273 (2004).
pubmed: 15325294
doi: 10.1016/j.ab.2004.05.055